Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor Vlll and/or activated blood coagulation factor Vlll.
The present invention is based on the discovery that by administering a predetermined dosing regimen of a pharmaceutical composition that comprises a bi-specific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X, it is possible to more effectively prevent and/or treat a disease that develops or progresses as a result of a decrease or loss of the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.
